Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial

Dina Visca, Vicky Tsipouri, Letizia Mori, Ashi Firouzi, Sharon Fleming, Morag Farquhar, Elizabeth Leung, Toby M Maher, Paul Cullinan, Nick Hopkinson, Athol U Wells, Winston Banya, Jennifer A Whitty, Huzaifa Adamali, Lisa G Spencer, Piersante Sestini, Elisabetta A Renzoni, Dina Visca, Vicky Tsipouri, Letizia Mori, Ashi Firouzi, Sharon Fleming, Morag Farquhar, Elizabeth Leung, Toby M Maher, Paul Cullinan, Nick Hopkinson, Athol U Wells, Winston Banya, Jennifer A Whitty, Huzaifa Adamali, Lisa G Spencer, Piersante Sestini, Elisabetta A Renzoni

Abstract

Background: Fibrotic interstitial lung diseases (ILDs) are chronic and often progressive conditions resulting in substantial morbidity and mortality. Shortness of breath, a symptom often linked to oxygen desaturation on exertion, is tightly linked to worsening quality of life in these patients. Although ambulatory oxygen is used empirically in their treatment, there are no ILD-specific guidelines on its use. To our knowledge, no studies are available on the effects of ambulatory oxygen on day-to-day life in patients with ILD.

Methods/design: Ambulatory oxygen in fibrotic lung disease (AmbOx) is a multicentre, randomised controlled crossover trial (RCT) funded by the Research for Patient Benefit Programme of the National Institute for Health Research. The trial will compare ambulatory oxygen used during daily activities with no ambulatory oxygen in patients with fibrotic lung disease whose oxygen saturation (SaO2) is ≥94% at rest, but drops to ≤88% on a 6-min Walk Test. The randomised controlled trial (RCT) will evaluate the effects on health status (measured by the King's Brief ILD Questionnaire: K-BILD) of ambulatory oxygen used at home, at an optimal flow rate determined by titration at screening visit, and administered for a 2-week period, compared to 2 weeks off oxygen. Key secondary outcomes will include breathlessness on activity scores, as measured by the University of California San Diego Shortness of Breath Questionnaire, global patient assessment of change scores, as well as quality of life scores (St George's Respiratory Questionnaire), anxiety and depression scores (Hospital Anxiety and Depression Scale), activity markers measured by SenseWear Armbands, pulse oximetry measurements, patient-reported daily activities, patient- and oxygen company-reported oxygen cylinder use. The study also includes a qualitative component and will explore in interviews patients' experiences of the use of a portable oxygen supply and trial participation in a subgroup of 20 patients and carers.

Discussion: This is the first RCT of the effects of ambulatory oxygen during daily life on health status and breathlessness in fibrotic lung disease. The results generated should provide the basis for setting up ILD-specific guidelines for the use of ambulatory oxygen.

Trial registration: National Clinical Trials Registry, identifier: NCT02286063 . Registered on 8 October 2014 (retrospectively registered).

Keywords: Activity measures; Ambulatory oxygen; Fibrotic interstitial lung disease; Health status; Oxygen desaturation; Quality of life; Shortness of breath.

Figures

Fig. 1
Fig. 1
SPIRIT Schedule of Events

References

    1. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med. 2005;99(4):408–14. doi: 10.1016/j.rmed.2004.09.005.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111-117.
    1. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med. 1997;155(5):1657–64. doi: 10.1164/ajrccm.155.5.9154872.
    1. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease. Chest. 1984;85(1):69–74. doi: 10.1378/chest.85.1.69.
    1. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration. 1983;44(2):118–27. doi: 10.1159/000194537.
    1. Charlie S, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med. 2005;11:452–5. doi: 10.1097/01.mcp.0000174250.38188.6d.
    1. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:1150–7. doi: 10.1164/rccm.200405-578OC.
    1. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a 6-minute Walk Test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–90. doi: 10.1164/rccm.200302-219OC.
    1. Bye PT, Anderson SD, Woolcock AJ, Young IH, Alison JA. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. Am Rev Respir Dis. 1982;126(6):1005–12.
    1. Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J. 2011;38(4):987–90. doi: 10.1183/09031936.00190710.
    1. Frank RC, Hicks S, Duck AM, Spencer L, Leonard CT, Barnett E. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J. 2012;40(1):269–70. doi: 10.1183/09031936.00007712.
    1. Nishiyama O, Miyajima H, Fukai Y, Yamazaki R, Satoh R, Yamagata T, et al. Effect of ambulatory oxygen on exertional dyspnoea in IPF patients without resting hypoxemia. Respir Med. 2013;107(8):1241–6. doi: 10.1016/j.rmed.2013.05.015.
    1. Troy L, Young I, Munoz P, Taylor N, Webster S, Lau E, et al. Does supplemental oxygen increase exercise endurance in patients with idiopathic pulmonary fibrosis? Respirology. 2014;19:95. doi: 10.1111/resp.12417_5.
    1. Sharp C, Adamali H, Millar AB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2016;7
    1. Hardinge M, Suntharalingam J, Wilkinson T, British Thoracic Society Guideline update: The British Thoracic Society Guidelines on home oxygen use in adults. Thorax. 2015;70(6):589–91. doi: 10.1136/thoraxjnl-2015-206918.
    1. Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804–10. doi: 10.1136/thoraxjnl-2012-201581.
    1. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnoea measure: the UCSD shortness of breath questionnaire. Chest. 1998;113:619–24. doi: 10.1378/chest.113.3.619.
    1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15. doi: 10.1016/0197-2456(89)90005-6.
    1. Jones PW, Quirk FH, Baverstock CM. The St. George’s Respiratory Questionnaire. Resp Med. 1991;85(Suppl B):25–31. doi: 10.1016/S0954-6111(06)80166-6.
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Borg GA. Psychophysical basis of perceived exertion. Med Sci Sports Exerc. 1982;14:377–81.
    1. Arnold E, Bruton A, Donovan-Hall M, Fenwick A, Dibb B, Walker E. Ambulatory oxygen: why do COPD patients not use their portable systems as prescribed? A qualitative study. BMC Pulm Med. 2011;11:9. doi: 10.1186/1471-2466-11-9.
    1. Patel AS, Siegert RJ, Keir GJ, Bajwah S, Barker RD, Maher TM, et al. The minimal important difference of the King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med. 2013;107(9):1438–43. doi: 10.1016/j.rmed.2013.06.009.
    1. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–60. doi: 10.1056/NEJMsr1203730.
    1. Hill K, Dolmage TE, Woon L, Goldstein R, Brooks D. Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. Thorax. 2010;65(6):486–91. doi: 10.1136/thx.2009.128702.
    1. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel H, Giavedoni S, et al. PROactive Consortium. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J. 2013;42(5):1205–15. doi: 10.1183/09031936.00134312.
    1. Follick M, Ahem D, Laser-Wolston N. Evaluation of a daily activity diary for chronic pain patients. Pain. 1984;19:373–82. doi: 10.1016/0304-3959(84)90083-6.
    1. Moore R, Berlowitz D, Denehy L, Jackson B, McDonald CF. Comparison of pedometer and activity diary for measurement of physical activity in chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2009;29(1):57–61. doi: 10.1097/HCR.0b013e318192786c.
    1. Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. London: Sage Publications; 2006.
    1. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, editors. Analyzing qualitative data. London: Routledge; 1994. pp. 173–94.
    1. O’Cathain A, Murphy E, Nicholl J. Why, and how, mixed methods research is undertaken in health services research in England: a mixed methods study. BMC Health Serv Res. 2007;7:85. doi: 10.1186/1472-6963-7-85.
    1. Barbour RS. The case for combining qualitative and quantitative approaches in health and services research. J Health Serv Res Policy. 1999;4:39–43. doi: 10.1177/135581969900400110.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren